Inherited determinants of early recurrent somatic mutations in prostate cancer.

TitleInherited determinants of early recurrent somatic mutations in prostate cancer.
Publication TypeJournal Article
Year of Publication2017
AuthorsRomanel A, Garritano S, Stringa B, Blattner M, Dalfovo D, Chakravarty D, Soong D, Cotter KA, Petris G, Dhingra P, Gasperini P, Cereseto A, Elemento O, Sboner A, Khurana E, Inga A, Rubin MA, Demichelis F
JournalNat Commun
Volume8
Issue1
Pagination48
Date Published2017 06 29
ISSN2041-1723
KeywordsCell Line, Tumor, Gene Expression Regulation, Neoplastic, Genotype, Humans, Male, Mutation, Neoplasm Recurrence, Local, Prostatic Neoplasms, Transcriptome
Abstract

Prostate cancer is a highly heritable molecularly and clinically heterogeneous disease. To discover germline events involved in prostate cancer predisposition, we develop a computational approach to nominate heritable facilitators of somatic genomic events in the context of the androgen receptor signaling. Here, we use a ranking score and benign prostate transcriptomes to identify a non-coding polymorphic regulatory element at 7p14.3 that associates with DNA repair and hormone-regulated transcript levels and with an early recurrent prostate cancer-specific somatic mutation in the Speckle-Type POZ protein (SPOP) gene. The locus shows allele-specific activity that is concomitantly modulated by androgen receptor and by CCAAT/enhancer-binding protein (C/EBP) beta (CEBPB). Deletion of this locus via CRISPR-Cas9 leads to deregulation of the genes predicted to interact with the 7p14.3 locus by Hi-C chromosome conformation capture data. This study suggests that a polymorphism at 7p14.3 may predispose to SPOP mutant prostate cancer subclass through a hormone-dependent DNA damage response.Prostate cancer is a heterogeneous disease, and many cases show somatic mutations of SPOP. Here, the authors show that a non-coding polymorphic regulatory element at 7p14.3 may predispose to SPOP mutant prostate cancer subclass through a hormone dependent DNA damage response.

DOI10.1038/s41467-017-00046-0
Alternate JournalNat Commun
PubMed ID28663546
PubMed Central IDPMC5491529